1,523 reports of this reaction
3.5% of all OSELTAMIVIR PHOSPHATE reports
#4 most reported adverse reaction
NAUSEA is the #4 most commonly reported adverse reaction for OSELTAMIVIR PHOSPHATE, manufactured by Genentech, Inc.. There are 1,523 FDA adverse event reports linking OSELTAMIVIR PHOSPHATE to NAUSEA. This represents approximately 3.5% of all 43,488 adverse event reports for this drug.
Patients taking OSELTAMIVIR PHOSPHATE who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is moderately reported among OSELTAMIVIR PHOSPHATE users, representing a notable but not dominant share of adverse events.
In addition to nausea, the following adverse reactions have been reported for OSELTAMIVIR PHOSPHATE:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 1,523 FDA reports for OSELTAMIVIR PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 3.5% of all adverse event reports for OSELTAMIVIR PHOSPHATE, making it a notable side effect.
If you experience nausea while taking OSELTAMIVIR PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.